• Palonosetron Hydrochloride: Precision Renal Transporter Inhi

  2026-05-15

  Explore the dual functionality of Palonosetron hydrochloride as both a selective 5-HT3 receptor antagonist and a potent OCT2/MATE1 renal transporter inhibitor. This article delivers advanced insights and practical protocol guidance for translational oncology research.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-05-14

  This study reveals that phenothiazines, including perphenazine, significantly enhance the antibacterial activity of macrophages by inducing reactive oxygen species (ROS) and autophagy. These findings highlight a promising host-directed therapy strategy against intracellular bacterial infections, offering an alternative to conventional antibiotics.

• Lactate-GPR81/FARP1 Pathway Enables Insulin-Independent Gluc

  2026-05-14

  This study demonstrates that L-lactate activates the GPR81/FARP1 signaling axis, promoting glucose uptake in skeletal muscle independently of insulin. These findings define a novel metabolic control mechanism and highlight GPR81 as a potential therapeutic target for hyperglycemia.

• MG-132 in Apoptosis and Cell Cycle Arrest: Optimizing Workfl

  2026-05-13

  MG-132, a potent peptide aldehyde proteasome inhibitor, unlocks advanced control over apoptosis and cell cycle arrest studies. This article provides actionable protocols, troubleshooting strategies, and key insights drawn from the latest research—including TDP-43 aggregation mechanisms—empowering researchers to design robust cancer and neurodegeneration experiments.

• Disulfiram: Dopamine β-Hydroxylase Inhibitor in Cancer Resea

  2026-05-13

  Disulfiram, a clinically established dopamine β-hydroxylase inhibitor, now empowers advanced cancer and apoptosis research thanks to its unique copper-complexed proteasome inhibition. This article guides researchers through optimized workflows, troubleshooting, and data-driven applications that maximize the impact of Disulfiram in experimental and translational oncology.

• CAY10499: Lipase Inhibition Illuminates Macrophage Metabolic

  2026-05-12

  Explore the scientific and translational significance of CAY10499, a potent inhibitor of human hormone sensitive lipase, in dissecting macrophage lipid metabolism and immune modulation. This article uniquely connects lipase inhibition to macrophage differentiation strategies for advanced disease models.

• SB 203580: A Precision Tool for Dissecting p38 MAPK in Neuro

  2026-05-12

  Explore how SB203580, a selective p38 MAPK inhibitor, advances neuroinflammation and pain pathway research. This article delivers new assay insights by integrating mechanistic depth and recent findings on peripheral sensitization.

• T-5224 (C-Fos/AP-1 Inhibitor): Precision Control of Neuroinf

  2026-05-11

  Explore the advanced applications of T-5224, a selective C-Fos/AP-1 inhibitor, in dissecting neuroinflammatory pathways and mechanotransduction. This article uniquely bridges transcriptional modulation with touch- and pain-related signaling, offering a deeper scientific perspective for inflammation and arthritis research.

• Bedaquiline at the Forefront: Mechanism, Strategy, and Impac

  2026-05-11

  This article offers translational researchers a deep mechanistic and strategic roadmap for leveraging Bedaquiline—a diarylquinoline antibiotic—across tuberculosis and cancer metabolism research. Integrating recent host-directed therapy advances, competitive context, and protocol best practices, it positions APExBIO's Bedaquiline as a uniquely versatile tool for next-generation experimental design.

• Wortmannin: Precision PI3K Inhibitor for Cancer Research Wor

  2026-05-10

  Wortmannin is a potent, selective PI3K inhibitor that unlocks advanced experimental workflows for dissecting PI3K/Akt/mTOR signaling and ferroptosis resistance in cancer models. This article demystifies practical use-cases, troubleshooting, and protocol enhancements to help researchers leverage Wortmannin’s unique properties for robust, reproducible results.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-05-09

  Palonosetron hydrochloride provides unparalleled selectivity and durability in 5-HT3 receptor antagonism, streamlining both in vitro and in vivo antiemetic research. This article unpacks advanced workflows, actionable troubleshooting, and evidence-backed protocol enhancements for cancer and transporter studies.

• Tetraethylammonium Chloride: Applied Workflows in K+ Channel

  2026-05-09

  Tetraethylammonium chloride (TEAC) is a gold-standard tool for dissecting potassium channel function across vascular, neuronal, and endocrine systems. This article translates high-impact bench research into actionable workflows, highlighting TEAC’s use as a precise K+ channel inhibitor, with troubleshooting and protocol optimization tips for reproducible, high-fidelity data.

• LC-Thalamic Reticular Pathway Links Pain and Attention Defic

  2026-05-08

  This study reveals that the locus coeruleus (LC)-to-thalamic reticular nucleus (TRN) circuit plays a causal role in the comorbidity of chronic pain and attention deficit-like behaviors. Using chemogenetic and optogenetic tools, the authors demonstrate that modulating LC activity can bidirectionally control both pain hypersensitivity and attentional deficits, highlighting a novel neural substrate for these overlapping disorders.

• GPR107 Deficiency Aggravates Diabetic Nephropathy via Podocy

  2026-05-07

  Xu et al. reveal that loss of GPR107 in podocytes intensifies diabetic nephropathy by disrupting collagen IV turnover and enhancing angiotensin II receptor-mediated calcium signaling. These findings clarify a mechanistic link between podocyte endocytosis and glomerular fibrosis, highlighting GPR107 as a potential therapeutic target.

• RCN2-UBR5-PPP2CA Axis Drives ESCC Metastasis via PI3K-Akt Ac

  2026-05-07

  This study identifies reticulocalbin 2 (RCN2) as a key driver of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) through UBR5-mediated degradation of PPP2CA, leading to PI3K-Akt pathway activation. The findings highlight a novel molecular axis for therapeutic targeting in aggressive ESCC and advance understanding of chemoresistance mechanisms.

450 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page